Epinastina [Spanish] en es it fr

Epinastina [Spanish] Brand names, Epinastina [Spanish] Analogs

Epinastina [Spanish] Brand Names Mixture

  • No information avaliable

Epinastina [Spanish] Chemical_Formula


Epinastina [Spanish] RX_link


Epinastina [Spanish] fda sheet

Epinastina_[Spanish] FDA

Epinastina [Spanish] msds (material safety sheet)

Epinastina_[Spanish] MSDS

Epinastina [Spanish] Synthesis Reference

No information avaliable

Epinastina [Spanish] Molecular Weight

249.311 g/mol

Epinastina [Spanish] Melting Point

205 - 208 oC

Epinastina [Spanish] H2O Solubility

No information avaliable

Epinastina [Spanish] State


Epinastina [Spanish] LogP


Epinastina [Spanish] Dosage Forms

Opthalmic solution (0.05%)

Epinastina [Spanish] Indication

For the prevention of itching associated with allergic conjunctivitis.

Epinastina [Spanish] Pharmacology

Epinastine is an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes. Epinastine is indicated for the prevention of itching associated with allergic conjunctivitis. Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2 receptor. Epinastine also possesses affinity for the a1-, a2-, and 5-HT2 -receptors. Epinastine does not penetrate the blood/brain barrier and, therefore, is not expected to induce side effects of the central nervous system.

Epinastina [Spanish] Absorption

The absolute bioavailability of epinastine is about 40%.

Epinastina [Spanish] side effects and Toxicity

No information avaliable

Epinastina [Spanish] Patient Information

Information for Patients: Patients should be advised not to wear a contact lens if their eye is red. ELESTAT™ should not be used to treat contact lens related irritation. The preservative in ELESTAT™, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of ELESTAT™ and may be reinserted after 10 minutes following its administration.

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Bottle should be kept tightly closed when not in use.

Epinastina [Spanish] Organisms Affected

Humans and other mammals